Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dianeal is a sterile, non-pyrogenic peritoneal dialysis solution manufactured by Baxter, used primarily for the treatment of end-stage renal disease (ESRD) through continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). It functions by utilizing dextrose as an osmotic agent to create a concentration gradient across the peritoneal membrane, facilitating the removal of excess fluid (ultrafiltration) and metabolic waste products, such as urea and creatinine, from the blood. The solution also contains essential electrolytes—including sodium, chloride, calcium, and magnesium—and lactate as a buffering agent to help maintain systemic acid-base and electrolyte balance. In clinical research, such as studies conducted at the Chinese PLA General Hospital, Dianeal often serves as the gold-standard comparator for evaluating the efficacy and safety of new peritoneal dialysate formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dianeal.